Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.

摘要: Background: A broader extent of amino acid substitutions in the integrase HIV-2 compared with HIV-1 might enable greater cross-resistance between raltegravir and dolutegravir infection. Few studies have examined virological response to patients that failed raltegravir. Methods: All recorded Spanish cohort were examined. The coding region was sequenced viraemic patients. Changes associated resistance recorded. Results: From 319 HIV-2-infected cohort, 53 sequences from 30 individuals obtained (20 naive 10 experienced). Only one secondary mutation (E138A) found 20 raltegravir-naive For raltegravir-experienced individuals, profile 9 as follows: N155H+A153G/S (four); Y143G+A153S (two); Q148R+G140A/S Y143C+Q91R (one). Of note, all Y143G N155H developed a rare non-polymorphic at codon 153. Rescue therapy given 5 these After > 6months on therapy, three baseline experienced viral rebound. In two them replaced by Q148K/R another G118R. Conclusions: wide repertoire mutations gene occur failing Although may allow successful rescue most failures, we report characterize cases patients, emerging variants Q148K Q148R novel change